Clinical Trial

Clinical Trial of CMD63 Chimeric Antigen Receptor T-cell (CAR T-cell) in Children With Acute Lymphoblastic Leukemia (ALL)

Study acronym: CMD63
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase 1 clinical trial to evaluate the safety and early efficacy of Chimeric Antigen Receptor T-cell (CAR T-cell) with IL-7Rα signaling targeting CD19 in children with relapsed and refractory B-cell Acute Lymphoblastic Leukemia (ALL) after complete standard treatments.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-14.
Status change: Not Yet Recruiting → Recruiting 2026-02-26
Trial Details
NCT Number NCT07078929
Lead Sponsor Chulalongkorn University
Collaborators: King Chulalongkorn Memorial Hospital
Conditions Relapse B Acute Lymphoblastic Leukemia, Refactory Childhood Acute Lymphoblastic Leukemia
Enrollment 16 participants
Start Date 2026-01-01
Primary Completion 2026-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-02